Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the ...
Health care executives continue to reimagine and reshape their organizations. Their ideas were developing in real time during ...
While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...
The desire of digital health companies to scale through mergers and acquisitions or partnerships was one of the most ...
Kyverna Therapeutics, Inc., a leading biotechnology company focusing on autoimmune diseases, revealed its strategic priorities for the year 2025 and anticipated milestones in a recent press release on ...
The 43 rd Annual Healthcare J.P. Morgan Healthcare Conference kicked off in San Francisco, California earlier this week. Notable executives from analytical science companies were invited to speak ...
What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...
Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...
This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...
San Francisco law enforcement and city leaders are gearing up for a big month ahead and are warning people to be on alert for ...
Reminders of the killing of UnitedHealthcare CEO Brian Thompson were everywhere at this year's J.P. Morgan conference.